CTLA4 and leukemia: Additionally, Kit M pretreatment of samples from patients who relapsed after allo-HCT leads to reduced ICM/ICML (e.g., CTLA4, 2B4 et al.)-expressing DC compared to controls (Figure 2), which could be associated with reduced immunosuppressive effects in leukemia.